---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-124097"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-11-29T23:59:59+00:00"
generated_at: "2026-05-29T13:03:39.448283+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics announces 1-for-33 reverse stock split effective Dec 4, 2024

## Summary
- Reverse split ratio 1-for-33; effective 12:01 a.m. ET Dec 4, 2024; new CUSIP 89357L402.
- Post-split shares outstanding approx 696,233 (includes recent private placement shares).
- Split intended to regain compliance with Nasdaq minimum $1.00 bid price; no assurance of continued listing.
- Fractional shares rounded up; no change in authorized shares; symbol RNAZ remains.
- Vstock Transfer acting as exchange agent; stockholders need not take action.

## SEC filing metadata
- accession: 0001104659-24-124097
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924124097/0001104659-24-124097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924124097/tm2429720d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-124097
- JSON: https://secwatch.observer/filing/0001104659-24-124097.json
- Plain text: https://secwatch.observer/filing/0001104659-24-124097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.